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Recently several endoscopic fluorescence detection systems have been developed. In some of
them, laser light was used for the excitation ofautofluorescence, and sophisticated techniques
were also necessary to amplify the fluorescence signal as well.
The result offluorescence diagnosis using a simple system with a conventional Xenon lamp
excitation and an image intensifier is reported. The respective results of sensitivity and
positive predictive values of cancer plus dysplasia were 66%, and 62% by standard
bronchoscopy and 92% and 88% by the newly developed autofluorescence system. In this
paper, developed endoscope for detection of tissue/mucosal autofluorescence without the
application of any photosensitizing agents or use of any lasers is evaluated.
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INTRODUCTION
The number ofearly stage lung cancer has increased
in recent years in Japan, mainly due to the common
use of sputum cytology for high risk patients or
symptomatic patients in Japan. If central type lung
cancer is detected at an early stage, endoscopic
treatment, especially photodynamic therapy can
obtain a favorable therapeutic response [1-3], thus
early detection is a goal of leading facilities in the
world. Since central type early stage lung cancer
shows no abnormality on chest X-ray or even on
helical CT, endoscopy is the only method to detect
these lesions. However, early cancer, especially
carcinoma in situ, shows only subtle mucosal
changes [4], thus repeated examinations are some-
times necessary to localize the lesion [5]. When
localization fails in cases with positive sputum
cytology, blind brushing or washing cytology
examination of segmental or subsegmental bronchi
is commonly performed [6]. Photodynamic diag-
nosis is another approach to detect these lesions [7]
but photosensitizer cannot be used routinely. To
overcome this problem, Lam and Palcic created a
fluorescence detection system [8-11]. The principle
of this system is based on the phenomenon that the
intensity of autofluorescence of tumor is different
from that ofnormal tissue illuminated by light with
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a specific wavelength. Their Lung Imaging Fluo-
rescence Endoscope (LIFE) system employs laser
light for the excitation of autofluorescence, and
sophisticated techniques to amplify the fluorescence
sign [10,11]. Even experienced bronchoscopists
sometimes fail to localize dysplastic lesions, inwhich
bronchial mucosal changes are extremely subtle. In
the multistep carcinogenesis theory, dysplasia has
been considered as one of the precancerous status,
which we have proved by animal experiments and
immunohistochemical studies [12,13].
The objective of the present study is to judge if a
simple fluorescence endoscopy system with a con-
ventional Xenon lamp could be useful in detecting
early cancer and dysplasia of the bronchus.
MATERIALS AND METHODS
Fluorescence Endoscope
A prototype of the System of Autofluorescence
Endoscopy (SAFE-1000, Asahi Optical Co., Ltd.,
Tokyo, Japan) was used in this study. A conven-
tional Xenon light equipped with a special filter was
used as an excitation light source instead of laser
light. Infrared light was eliminated by the infrared-
cut filter and only 420-480nm excitation light was
delivered through an excitation filter and trans-
mitted via an image guide. The intensified auto-
fluorescence of normal mucosa appeared green
on the image monitor, although abnormal areas
showed a cold image caused by the lack of
autofluorescence. The camera which contained a
fluorescence filter, image intensifier, and a TV
camera was attached to the eyepiece ofthe broncho-
scope. Only 520-600nm light passed through the
fluorescence filter, and this autofluorescence was
amplified by the image intensifier.
The intensified image is processed simultaneously
on the video monitor in real time [14].
Subjects
A total of 72 cases were studied and 147 sites were
biopsied from January 1997 to June 1997 in Tokyo
Medical University Hospital. The subjects were
classified into three categories; cases with lung
cancer, 42 cases (58%), abnormal sputum cytology
findings, 16 cases (22%) and smokers with recurrent
symptoms, 14 cases (19%), respectively. Informed
consent was obtained in all cases. At first, conven-
tional bronchoscopy (C.B.) using an FB18RX
(Asahi Optical Co., Ltd., Tokyo, Japan) was
performed under local anesthesia and areas suspi-
cious for cancer or dysplasia were noted for sub-
sequent biopsy. After the C.B. procedure, the
bronchoscope was placed in the trachea of the
patient, fluorescence examination was begun by
attaching a fluorescence camera to the eye-piece
of the bronchoscope and by attaching the infrared
filter to the Xenon lamp. Areas with decreased
green autofluorescence were objectively noticed
and diagnosed as suspicious by bronchoscopists.
The biopsy were taken from all abnormal areas
discovered by the C.B. or SAFE, or both. In this
study, negative control biopsies (C.B. normal and
SAFE normal) were not routinely obtained. Biopsy
Specimens were interpreted by an experienced
pathologist and pathological diagnosis was the gold
standard to decide the diagnostic accuracy.
RESULTS
A total of 72 subjects were enrolled in this study;
48 men and 24 women, aged 49-79 (Table I). The
enrolled patients were classified into three groups.
The first group consisted of 42 patients (58%) with
known lung cancer. In 24 patients, primary lesions
were visible by both C.B. and SAFE, but in the
other 18 cases, tumors were not recognized because
the primary lesions were located in periphery of the
lung. The results of spectral analysis with SAFE of
an invasive squamous cell carcinoma at the orifice
ofthe right middle lobe bronchus is shown in Fig. 1.
The difference of fluorescence intensity between
normal and tumor tissue was detected at 500-
600nm wavelength.
The second group consisted of 16 cases (22%)
with abnormal sputum cytology findings butFLUORESCENCE DIAGNOSIS WITH SAFE 101
normal chest X-ray. Early cancer was detected in
4 cases, dysplasia was diagnosed in 9 cases but the
lesion was unknown in 3 cases.
The third group consisted of 14 cases (19%), all
ofwhom currently smoked, with a history of more
TABLE Characteristics of enrolled patients (72 cases)
I. Lung cancer (42 cases)
Endoscopically recognized/unrecognized 24/18
Squamous cell carcinoma 20
Adenocarcinoma 21
Small cell carcinoma
Dysplasia was found in 11 cases (26%)
II. Abnormal sputum cytology findings (16 cases)
Early cancer 4
Dysplasia 9
Origin unknown 3
III. Smokers with symptoms (14 cases)
Dysplasia 2
Normal/inflammation 12
than 20 pack-years. Dysplasia was found in 2 cases,
chronic inflammation in 10 cases, and the rest of 2
patients were pathologically normal.
A total of 147 sites were biopsied. A comparison
of endoscopic findings and pathological diagnosis
of the biopsy specimens is shown in Table II.
Invasive cancer was detected at 24 sites (16%), all
ofwhich were correctly diagnosed by both C.B. and
SAFE. Early cancerwas detected at4 sites (6%), 3 of
them were recognized by both C.B. and SAFE. The
remaining site was almost unrecognized by C.B. but
objectively recognized by SAFE. Figure 2 shows the
endoscopic findings of this case, a 70 year-old man,
who had been referred to our clinic because of
abnormal sputum cytology findings. A cold spot
was recognized at the orifice of left B6 by SAFE,
while C.B. findings were almost normal. Biopsy
revealed squamous cell carcinoma.
length(ha)
FIGURE Spectrum analysis of normal and tumor tissue was performed during, fluorescence examination of cases with
invasive squamous cell cancer. The intensity of autofluorescence decreased in tumor tissue compared with that of normal tissue
excited at 440 nm. (1: normal, 2: tumor).102 M. KAKIHANA et al.
TABLE II Results of endoscopic findings and pathology
(147 sites)
SAFE negative SAFE positive
Invasive cancer (n 24)
CB positive
Early cancer (n 4)
CB negative
CB positive
Dysplasia (n 51)
CB negative
CB positive
Normal/Inflammation (n 68)
CB negative
CB positive
24(100%)
(25%)
3(75%)
0 (0%) 25 (49%)
6(12%) 20 (39%)
22 (32%) 15 (22%)
16(24%) 15(22%)
A total of 51 sites were pathologically diagnosed
for dysplasia. C.B. diagnosed 26 sites (specificity:
51%) and SAFE diagnosed 45 sites (specificity:
88%). Figure 3 shows a typical case of dysplasia
negative on C.B. negative, and positive on SAFE.
This case, a 67 year-old man, was referred to our
hospital for detailed examination of abnormal
sputum cytology findings. The cold spot was noted
in right B5 by SAFE, although C.B. findings were
normal. Biopsy revealed moderatly differentiated
dysplasia. In relation to sensitivity, C.B. showed
FIGURE 2 Conventional and fluorescence bronchoscopic findings of early squamous cell carcinoma in left B6. The lesion was
recognized by SAFE although C.B. findings were normal.
FIGURE 3 Conventional and fluorescence bronchoscopic findings of dysplasia in right B5. The lesion was recognized by the
SAFE although C.B. findings were normal.FLUORESCENCE DIAGNOSIS WITH SAFE 103
TABLE III Summary of clinical data
CB(% SAFE(%)
Sensitivity
Cancer and dysplasia 66 92
Dysplasia 51 88
Positive predictive value 62 71
Specificity 54 56
54% and the SAFE system, 56%. The summary of
diagnostic rate is shown in Table III.
DISCUSSION
Recent advances in molecular biology suggest a
multistep theory of carcinogenesis [15]. Thiberville
reported genetic losses in progressive precancerous
lesions. Also Hirano et al. reported hyperprolifera-
tion high frequency p53 abnormality in dysplasia
and early squamous cell carcinoma [13]. As dyspla-
sia might be one premalignant condition, early
detection and follow up ofthese lesions are essential.
Chemoprevention with vitamin B12 was effective in
reversing persistent dysplasia to normal status [16].
Photodynamic therapy was successful in the treat-
ment of central type early stage lung cancer and it
was approved to be covered by the National Health
Insurance in Japan [17]. While the management of
precancerous and cancerous lesions ofthe bronchus
have improved, early detection ofsuch lesions is still
a challenge for bronchoscopists.
Sputum cytology examination is one method to
detect central type early cancer or precancerous
lesions, but sometimes the origin of abnormal cells
cannot be determined. Carcinoma in situ or early
cancer are difficult to localize, because these lesions
may not always show enough macroscopically
recognizable changes in the bronchial mucosa [4].
Fluorescence diagnosis has been reported to
improve the detection rate of intraepithelial lesions
in recent years [8-10,18]. The concept of fluores-
cence endoscopy depends on the fact that an
abnormal area has different autofluorescence from
that of normal areas. The normal area of the
bronchus shows green autofluorescence when
excited by blue light, but abnormal areas such as
cancer or a precancerous lesion show cold spots due
to decreased green autofluorescence [10,11]. The
LIFE system has been distributed all over the world
and Lam et al. reported favorable results in their
multicenter clinical trial [19]. In the near future,
fluorescence diagnosis will be routinely used, there-
fore the need to make available a simple and
effective device at a relatively low cost, will become
necessary. One advantage of SAFE is that it uses a
standard Xenon lamp with filter [14].
In the present study, the diagnostic rate between
invasive cancer is same by C.B. and by SAFE. The
object of fluorescence evaluation is not to diagnose
advanced cancer, but the extent of the lesion could
be objectively observed by SAFE, which is useful
in the preoperative determination of the resection
line or to determine the extent of endoscopic local
treatment, such as photodynamic therapy. We
encountered one out of four cases of early cancer
which showed normal C.B. findings and abnormal
SAFE findings. The respective sensitivity of cancer
plus dysplasia and dysplasia was 66% and 51% with
C.B. and 92% and 88% with SAFE. We postulated
that this is a promising preliminary result for the
simplified autofluorescence system. On the average,
the fluorescence examination took a further 10 min
after the standard bronchoscopy procedure so that
this modality could be routinely used.
False positive results were frequent in cases with
bronchitis both in C.B. and SAFE. C.B. tended to
overdiagnose thickened bifurcation and the main
reason for false negative by SAFE was due to
increased cell layers by chronic inflammation, as
previously reported [8,9,18].
Our study suggests the possibility of fluorescence
diagnosis of subtle bronchial lesions with this sim-
ple device. Further developments of this device in a
muticenter study will be necessary to prove this
observation.
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